[December 15, 2016]

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology - Research and Markets

Research and Markets has announced the addition of the "Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology" report to their offering.

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inhibitory as well as stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microenvironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date, as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:

Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-ß/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:

Negative Immune Checkpoints:

- PD-1 (programmed cell death 1)

- PD-L1 (programmed cell death ligand 1 (PD-L1))

- CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)

- LAG-3 (Lymphocyte Activation Gene 3; CD223)

- TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)

- VISTA (V-region Ig-containing Suppressor of T-cell Activation) Receptor

- CEACAM1 (Carcino-Embryonic Antigen Cell Adhesion Molecule 1)

- BTLA (B- and T-Lymphocyte Attenuator)

- GARP (Glycoprotein A Repetitions Predominant)

- TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)

- IL-10 (Interleukin-10)

- B7-H3 (CD273)

Stimulatory Immune Checkpoints:

- CD40 (TNFSFR5)

- GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)

- OX40 (CD134; TNFSFR4)

- 4-1BB (CD137; TNFSFR9)

- CD27 (TNFSFR7)

- ICOS (Inducible Co-Stimulator)

Immunosuppressive tumor microenvronment:

- IDO (Indoleamine 2,3-dioxygenase)

- TDO (Tryptophan 2,3 dioxygenase)

- TGF-ß/R (Transforming Growth Factor beta/Receptor)

- CXCR4 (Chemokine Receptor Type 4)

- CSF-1R (Colony Stimulating Factor-1 Receptor)

- CD47 - SIRPa (Signal Regulatory Protein Alpha)

- Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine

- STING (STimulator of INterferon Genes) Receptor

- Others (e.g. arginase)

More than 90 unique molecules (mostly antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further 31 molecules are undergoing IND-enabling studies.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes

- Target (News - Alert)/Mechanism of Action

- Class of Compound

- Company

- Product Category

- Indication

- R&D Stage

- Additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

- Detailed report descriptions and tables of contents from the reports can be found on the respective product pages listed in the "Also Available" section below.

Key Topics Covered:

Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016

1. Programmed Cell Death 1 (PD-1. Receptor Antagonists)

- Specific Anti-PD-1 Antibodies

- Bispecific Anti-PD-1 Antibodies

- Non-Antibody PD-1 Receptor Antagonists

2. Programmed Cell Death 1 Receptor Ligand 1 (PD-L1. Inhibitors)

- Specific Anti-PD-L1 Antibodies

- Bispecific Anti-PD-L1 Antibodies

- Non-Antibody PD-L1 Inhibitors

3. Corporate PD-1 & PD-L1 Immune Checkpoint Inhibitor R&D Pipeline

Report 2: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

1. CTLA-4 Antagonists

- Yervoy (ipilimumab. monotherapy)

- Yervoy (ipilimumab. combination with Opdivo (nivolumab))

- Yervoy (ipilimumab. combination with other therapeutics)

- Tremelimumab monotherapy

- Tremelimumab combination with durvalumab

- Tremelimumab combination with other therapeutics

- Novel Specific CTLA-4 Antagonists

- Novel Bispecific CTLA-4 Antagonists

2. LAG-3 Antagonists

3. TIM-3 Antagonists

4. Inhibitors of Other Negative Immune Checkpoints

5. Corporate Immune Checkpoint Inhibitor R&D Pipelines

Report 3: Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

1. Immune Checkpoint Activators

- CD40 Agonists

- Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR. Stimulators)

- OX40 Agonists

- 4-1BB (CD137. Agonists)

- CD27 Agonists

- Inducible Co-Stimulator Molecule (ICOS. Agonists)

- Other Activators

2. Corporate Immune Checkpoint Activators R&D Pipeline

Report 4: Tumor Microenvironment Modulation via IDO, TGF-ß/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others

1. IDO & TDO Inhibitors

- Epacadostat Studies

- Indoximod Studies

- Novel IDO Inhibitors

- Novel TDO Inhibitors

- Dual IDO & TDO Inhibitors

2. TGF-beta/R Inhibitors

3. CXCR4 Antagonists & CXCL12 Inhibitors

4. CSF-1R Antagonists & CSF-1R tk Inhibitors

5. CD47 - SIRPa Pathway Inhibition

6. Adenosine Pathway

- Adenosine A2 Receptor (A2AR. Antagonists)

- CD73 (AMPase. & CD39 (ATP (News - Alert)/ADPase. Inhibitors and Adenosine Degradation)

7. STING Receptor Stimulators

8. Other Inhibitors of Immunosuppressive Tumor Microenvironment

9. Corporate Tumor Microenvironment Modulator R&D Pipelines

For more information about this report visit http://www.researchandmarkets.com/research/fcks44/competitor

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161215006229/en/

[ Back To TMCnet.com's Homepage ]